secretagogue - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	secretagogue	go back to main search page
Accession:	CHEBI:90414	browse the term
Definition:	A substance that causes another substance to be secreted.
Synonyms:	related_synonym:	secretagogues
	xref:	Wikipedia:Secretagogue

show annotations for term's descendants Sort by:
Rat (67) Mouse (75) Human (69) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (67)

acetohexamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

albumin

affects binding

Acetohexamide binds to ALB protein; Acetohexamide binds to ALB protein modified form

PMID:20435530 PMID:20829128 PMID:20956006 PMID:20974553 PMID:21612784

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

dehydrogenase/reductase 3

increases metabolic processing

DHRS3 protein results in increased metabolism of Acetohexamide

NCBI chr 5:156,747,939...156,782,420
Ensembl chr 5:156,747,962...156,782,417

chlorpropamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 8

multiple interactions

[KCNJ11 mutant form co-treated with ABCC8 mutant form] results in decreased susceptibility to Chlorpropamide

NCBI chr 1:96,598,568...96,679,563
Ensembl chr 1:96,598,647...96,679,510

G

angiotensin converting enzyme 2

decreases expression

Chlorpropamide results in decreased expression of ACE2 mRNA

NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977

G

arginine vasopressin

decreases secretion

Chlorpropamide results in decreased secretion of AVP protein modified form

NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression

Chlorpropamide results in increased expression of FOS mRNA

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

insulin 2

decreases expression
increases expression
multiple interactions

Chlorpropamide results in decreased expression of INS protein
Chlorpropamide results in increased expression of INS mRNA
Chlorpropamide inhibits the reaction [Glucose results in decreased secretion of INS protein]

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

potassium inwardly-rectifying channel, subfamily J, member 11

multiple interactions

[KCNJ11 mutant form co-treated with ABCC8 mutant form] results in decreased susceptibility to Chlorpropamide

NCBI chr 1:96,591,048...96,594,574
Ensembl chr 1:96,591,049...96,594,082

gliclazide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 8

multiple interactions

[KCNJ11 mutant form co-treated with ABCC8 mutant form] results in increased susceptibility to Gliclazide

NCBI chr 1:96,598,568...96,679,563
Ensembl chr 1:96,598,647...96,679,510

G

aldo-keto reductase family 1, member C3

decreases activity

Gliclazide results in decreased activity of AKR1C3 protein

NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873

G

albumin

affects binding
multiple interactions

Gliclazide binds to ALB protein
Gliclazide inhibits the reaction [[Streptozocin co-treated with Cholesterol, Dietary] results in increased secretion of ALB protein]

PMID:14871415 PMID:20974553

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

BCL2, apoptosis regulator

multiple interactions

Gliclazide inhibits the reaction [Glucose results in decreased expression of BCL2 protein]

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

caspase 3

multiple interactions
decreases expression

Gliclazide inhibits the reaction [Glucose results in increased expression of CASP3 protein]
Gliclazide results in decreased expression of CASP3 mRNA
Gliclazide inhibits the reaction [Acetic Acid results in increased expression of CASP3 protein]

PMID:18088078 PMID:32045587 PMID:33652124

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

multiple interactions

Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Gliclazide inhibits the reaction [Streptozocin results in decreased activity of CAT protein]

PMID:20307516 PMID:20643114 PMID:21439372

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

Gliclazide inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN1A mRNA]

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

glucose-6-phosphate dehydrogenase

multiple interactions

Gliclazide inhibits the reaction [Streptozocin results in decreased activity of G6PD protein]

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein]

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glyoxalase 1

multiple interactions

Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein]

NCBI chr20:8,663,617...8,681,661
Ensembl chr20:8,662,801...8,681,649

G

glutathione-disulfide reductase

multiple interactions

Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein]

PMID:20307516 PMID:21439372

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

glutathione S-transferase, mu 5

multiple interactions

Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA]

NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553

G

heme oxygenase 1

multiple interactions

Gliclazide inhibits the reaction [Hydrogen Peroxide results in increased expression of HMOX1 mRNA]
Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein]

PMID:12646174 PMID:21439372

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

intercellular adhesion molecule 1

multiple interactions

Gliclazide inhibits the reaction [[Streptozocin co-treated with Cholesterol, Dietary] results in increased expression of ICAM1 protein]; Gliclazide inhibits the reaction [Acetic Acid results in increased expression of ICAM1 protein]

PMID:14871415 PMID:32045587

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

interleukin 10

multiple interactions

Gliclazide inhibits the reaction [Acetic Acid results in decreased expression of IL10 protein]

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 beta

multiple interactions

Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein]; Gliclazide inhibits the reaction [Streptozocin results in increased expression of IL1B protein]

PMID:20307516 PMID:20643114 PMID:21439372

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein]; Gliclazide inhibits the reaction [Acetic Acid results in increased expression of IL6 protein]; Gliclazide inhibits the reaction [Streptozocin results in increased expression of IL6 protein]

PMID:20307516 PMID:20643114 PMID:21439372 PMID:32045587

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

multiple interactions

Gliclazide inhibits the reaction [Streptozocin results in decreased expression of and results in decreased secretion of INS1 protein]; Gliclazide inhibits the reaction [Streptozocin results in decreased expression of INS1 protein]

PMID:28330423 PMID:28625491

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

potassium inwardly-rectifying channel, subfamily J, member 11

multiple interactions

[KCNJ11 mutant form co-treated with ABCC8 mutant form] results in increased susceptibility to Gliclazide

NCBI chr 1:96,591,048...96,594,574
Ensembl chr 1:96,591,049...96,594,082

G

Kelch-like ECH-associated protein 1

multiple interactions

Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein]

NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862

G

mitogen activated protein kinase 1

multiple interactions

Gliclazide inhibits the reaction [Acetic Acid results in increased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

Gliclazide inhibits the reaction [Acetic Acid results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

multiple interactions

Gliclazide inhibits the reaction [Acetic Acid results in increased phosphorylation of MAPK8 protein]

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

myeloperoxidase

multiple interactions

Gliclazide inhibits the reaction [Acetic Acid results in increased activity of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

neutrophil cytosolic factor 1

multiple interactions

Gliclazide inhibits the reaction [[Streptozocin co-treated with Cholesterol, Dietary] results in increased expression of NCF1 protein]

NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646

G

NFE2 like bZIP transcription factor 2

multiple interactions

Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein]

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nitric oxide synthase 3

increases expression

Gliclazide results in increased expression of NOS3 protein

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

G

peroxisome proliferator-activated receptor gamma

multiple interactions

Gliclazide inhibits the reaction [Acetic Acid results in decreased expression of PPARG protein]

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein]; Gliclazide inhibits the reaction [Streptozocin results in increased expression of RELA protein]

PMID:20307516 PMID:20643114 PMID:21439372

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

superoxide dismutase 2

multiple interactions

Gliclazide inhibits the reaction [[Streptozocin co-treated with Cholesterol, Dietary] results in decreased expression of SOD2 protein]

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

tumor necrosis factor

multiple interactions
decreases expression

Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein]; Gliclazide inhibits the reaction [Streptozocin results in increased expression of TNF protein]
Gliclazide results in decreased expression of TNF protein

PMID:20307516 PMID:20643114 PMID:21439372

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF alpha induced protein 3

multiple interactions

Gliclazide inhibits the reaction [Hydrogen Peroxide results in increased expression of TNFAIP3 mRNA]

NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282

G

tumor protein p53

increases expression

Gliclazide results in increased expression of TP53 mRNA

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

glimepiride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases activity
multiple interactions

glimepiride results in decreased activity of ABCB11 protein
glimepiride inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]

PMID:20829430 PMID:23956101 PMID:24014644

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily C member 8

multiple interactions

[KCNJ11 mutant form co-treated with ABCC8 mutant form] results in decreased susceptibility to glimepiride

NCBI chr 1:96,598,568...96,679,563
Ensembl chr 1:96,598,647...96,679,510

G

aldo-keto reductase family 1, member C1

decreases activity

glimepiride results in decreased activity of AKR1C1 protein

NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326

G

aldo-keto reductase family 1, member C3

decreases activity

glimepiride results in decreased activity of AKR1C3 protein

NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873

G

calpain 1

increases expression

glimepiride results in increased expression of CAPN1 mRNA

NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177

G

calpain 10

increases expression

glimepiride results in increased expression of CAPN10 mRNA

NCBI chr 9:93,498,132...93,510,494
Ensembl chr 9:93,498,478...93,510,494

G

calpain 2

increases expression

glimepiride results in increased expression of CAPN2 mRNA

NCBI chr13:94,150,244...94,200,969
Ensembl chr13:94,150,240...94,200,969

G

caspase 3

increases activity
increases expression

glimepiride results in increased activity of CASP3 protein
glimepiride results in increased expression of CASP3 mRNA

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

[glimepiride results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

insulin 1

multiple interactions

[Plant Extracts co-treated with glimepiride] inhibits the reaction [Streptozocin results in decreased expression of INS1 protein]; glimepiride inhibits the reaction [Streptozocin results in decreased expression of INS1 protein]

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

insulin 2

decreases expression

glimepiride results in decreased expression of INS protein

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

potassium inwardly-rectifying channel, subfamily J, member 11

multiple interactions

[KCNJ11 mutant form co-treated with ABCC8 mutant form] results in decreased susceptibility to glimepiride

NCBI chr 1:96,591,048...96,594,574
Ensembl chr 1:96,591,049...96,594,082

G

nuclear receptor subfamily 1, group I, member 2

increases activity
multiple interactions

glimepiride results in increased activity of NR1I2 protein
[glimepiride results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

RT1 class Ib, locus M3, gene 1

affects expression

glimepiride affects the expression of HLA-G mRNA

NCBI chr20:1,323,976...1,328,126
Ensembl chr20:1,287,521...1,328,117

G

solute carrier organic anion transporter family member 1B2

multiple interactions

glimepiride affects the reaction [SLCO1B3 protein results in increased uptake of Atorvastatin]; glimepiride affects the reaction [SLCO1B3 protein results in increased uptake of Sulfobromophthalein]

NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981

G

solute carrier organic anion transporter family, member 2b1

multiple interactions

glimepiride inhibits the reaction [SLCO2B1 protein results in increased uptake of Atorvastatin]; glimepiride inhibits the reaction [SLCO2B1 protein results in increased uptake of Sulfobromophthalein]

NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353

G

tumor protein p53

increases expression

glimepiride results in increased expression of TP53 mRNA

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

glipizide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

multiple interactions
decreases activity

Glipizide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
Glipizide results in decreased activity of ABCB11 protein

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

aldo-keto reductase family 1, member C1

decreases activity

Glipizide results in decreased activity of AKR1C1 protein

NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326

G

aldo-keto reductase family 1, member C2

decreases activity

Glipizide results in decreased activity of AKR1C2 protein

NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764

G

aldo-keto reductase family 1, member C3

decreases activity

Glipizide results in decreased activity of AKR1C3 protein

NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873

tolbutamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

multiple interactions
decreases activity

Tolbutamide inhibits the reaction [ABCB1 protein results in increased uptake of quinidinium]
Tolbutamide results in decreased activity of ABCB1 protein

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily C member 8

multiple interactions

[KCNJ11 mutant form co-treated with ABCC8 mutant form] results in decreased susceptibility to Tolbutamide; ABCC8 gene SNP inhibits the reaction [Tolbutamide results in increased secretion of INS protein]; Tolbutamide inhibits the reaction [ABCC8 protein mutant form results in increased activity of KCNJ11 protein]

PMID:9568693 PMID:18025464 PMID:22209866

NCBI chr 1:96,598,568...96,679,563
Ensembl chr 1:96,598,647...96,679,510

G

albumin

affects binding

Tolbutamide binds to ALB protein

PMID:19596536 PMID:20435530 PMID:20956006 PMID:20974553

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

cyclin D1

increases expression

Tolbutamide results in increased expression of CCND1 protein

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin D3

increases expression

Tolbutamide results in increased expression of CCND3 protein

NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371

G

cyclin-dependent kinase inhibitor 1A

multiple interactions
increases expression

GJA1 promotes the reaction [Tolbutamide results in increased expression of CDKN1A protein]

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

increases expression

Tolbutamide results in increased expression of CDKN1B protein

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

cytochrome P450, subfamily 2, polypeptide 11

increases metabolic processing

CYP2C18 results in increased metabolism of Tolbutamide

NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066

G

cytochrome P450, family 2, subfamily c, polypeptide 24

increases metabolic processing
multiple interactions

CYP2C55 protein results in increased metabolism of Tolbutamide
[CYP2C55 protein results in increased metabolism of Tolbutamide] which results in increased chemical synthesis of 4'-hydroxytolbutamide

NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:236,873,967...236,936,238

G

cytochrome P450, family 2, subfamily C, polypeptide 6

increases metabolic processing
multiple interactions
increases hydroxylation

CYP2C19 protein results in increased metabolism of Tolbutamide
[CYP2C19 protein results in increased hydroxylation of Tolbutamide] which results in increased chemical synthesis of 4'-hydroxytolbutamide

PMID:18511451 PMID:30500380

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily c, polypeptide 66

multiple interactions
increases metabolic processing

[CYP2C66 protein results in increased metabolism of Tolbutamide] which results in increased chemical synthesis of 4'-hydroxytolbutamide

NCBI chr 1:237,078,517...237,169,841
Ensembl chr 1:237,078,517...237,169,650

G

cytochrome P450, family 2, subfamily c, polypeptide 79

increases hydroxylation

CYP2C8 protein results in increased hydroxylation of Tolbutamide

G

glucagon

increases secretion

Tolbutamide results in increased secretion of GCG protein

NCBI chr 3:47,113,914...47,122,958
Ensembl chr 3:47,113,914...47,122,929

G

gap junction protein, alpha 1

multiple interactions
increases expression

GJA1 promotes the reaction [Tolbutamide results in increased expression of CDKN1A protein]; Tolbutamide promotes the reaction [Bucladesine results in increased expression of GJA1 protein]
Tolbutamide results in increased expression of GJA1 protein

PMID:11741589 PMID:16718685

NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582

G

hexokinase 1

increases expression

Tolbutamide results in increased expression of HK1 protein

NCBI chr20:30,230,488...30,332,099
Ensembl chr20:30,230,486...30,332,131

G

insulin 1

affects secretion
multiple interactions

Tolbutamide affects the secretion of INS1 protein
[Tolbutamide co-treated with FR900359] inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Tolbutamide inhibits the reaction [arsenite inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; Tolbutamide inhibits the reaction [dimethylarsinous acid inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; Tolbutamide inhibits the reaction [methylarsonite inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; Tolbutamide promotes the reaction [Glucose results in increased secretion of INS1 protein]

PMID:9366569 PMID:31332465 PMID:37217659

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

insulin 2

multiple interactions
increases secretion

ABCC8 gene SNP inhibits the reaction [Tolbutamide results in increased secretion of INS protein]

PMID:9032110 PMID:9568693

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

potassium inwardly-rectifying channel, subfamily J, member 11

multiple interactions
decreases activity

[KCNJ11 mutant form co-treated with ABCC8 mutant form] results in decreased susceptibility to Tolbutamide; Tolbutamide inhibits the reaction [ABCC8 protein mutant form results in increased activity of KCNJ11 protein]
Tolbutamide results in decreased activity of KCNJ11 protein

PMID:18025464 PMID:22209866

NCBI chr 1:96,591,048...96,594,574
Ensembl chr 1:96,591,049...96,594,082

G

marker of proliferation Ki-67

decreases expression

Tolbutamide results in decreased expression of MKI67 protein

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

programmed cell death 4

decreases expression
increases expression

Tolbutamide results in decreased expression of PDCD4 mRNA
Tolbutamide results in increased expression of PDCD4 mRNA

NCBI chr 1:252,921,342...252,944,278
Ensembl chr 1:252,921,392...252,944,275

G

RB transcriptional corepressor 1

decreases phosphorylation

Tolbutamide results in decreased phosphorylation of RB1 protein

NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302

G

solute carrier family 2 member 1

increases expression

Tolbutamide results in increased expression of SLC2A1 mRNA; Tolbutamide results in increased expression of SLC2A1 protein

PMID:2682625 PMID:11835228

NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416

G

TNF alpha induced protein 3

decreases expression

Tolbutamide results in decreased expression of TNFAIP3 mRNA

NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282

G

tumor protein p53

increases expression

Tolbutamide results in increased expression of TP53 mRNA

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

tumor protein D52

decreases expression
increases expression

Tolbutamide results in decreased expression of TPD52 mRNA
Tolbutamide results in increased expression of TPD52 mRNA

NCBI chr 2:92,735,365...92,816,079
Ensembl chr 2:92,735,620...92,816,622

G

UDP-glucose 6-dehydrogenase

decreases expression

Tolbutamide results in decreased expression of UGDH protein

NCBI chr14:42,848,704...42,872,351
Ensembl chr14:42,848,854...42,872,354

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19880
role	19850
biological role	19848
biochemical role	19556
secretagogue	67
insulin secretagogue +	67

paths to the root